1. Home
  2. KALA vs FENG Comparison

KALA vs FENG Comparison

Compare KALA & FENG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KALA
  • FENG
  • Stock Information
  • Founded
  • KALA 2009
  • FENG 1998
  • Country
  • KALA United States
  • FENG China
  • Employees
  • KALA N/A
  • FENG N/A
  • Industry
  • KALA Biotechnology: Pharmaceutical Preparations
  • FENG Broadcasting
  • Sector
  • KALA Health Care
  • FENG Industrials
  • Exchange
  • KALA Nasdaq
  • FENG Nasdaq
  • Market Cap
  • KALA 26.2M
  • FENG 26.8M
  • IPO Year
  • KALA 2017
  • FENG 2011
  • Fundamental
  • Price
  • KALA $8.40
  • FENG $2.10
  • Analyst Decision
  • KALA Strong Buy
  • FENG
  • Analyst Count
  • KALA 3
  • FENG 0
  • Target Price
  • KALA $14.00
  • FENG N/A
  • AVG Volume (30 Days)
  • KALA 204.0K
  • FENG 4.1K
  • Earning Date
  • KALA 08-05-2025
  • FENG 08-12-2025
  • Dividend Yield
  • KALA N/A
  • FENG N/A
  • EPS Growth
  • KALA N/A
  • FENG N/A
  • EPS
  • KALA N/A
  • FENG N/A
  • Revenue
  • KALA N/A
  • FENG $97,280,369.00
  • Revenue This Year
  • KALA N/A
  • FENG N/A
  • Revenue Next Year
  • KALA N/A
  • FENG N/A
  • P/E Ratio
  • KALA N/A
  • FENG N/A
  • Revenue Growth
  • KALA N/A
  • FENG 1.04
  • 52 Week Low
  • KALA $2.92
  • FENG $1.28
  • 52 Week High
  • KALA $11.20
  • FENG $3.69
  • Technical
  • Relative Strength Index (RSI)
  • KALA 74.24
  • FENG 42.08
  • Support Level
  • KALA $5.35
  • FENG $2.28
  • Resistance Level
  • KALA $8.49
  • FENG $2.37
  • Average True Range (ATR)
  • KALA 0.79
  • FENG 0.10
  • MACD
  • KALA 0.24
  • FENG -0.02
  • Stochastic Oscillator
  • KALA 97.13
  • FENG 0.00

About KALA KALA BIO Inc.

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

About FENG Phoenix New Media Limited

Phoenix New Media Ltd is a media company providing premium content on an integrated platform across the internet, mobile and TV channels in China. The company organizes its operations into two main segments: Net advertising services and Paid services. It provides its content and services through three channels: ifeng.com channel, video channel, and mobile channel. The company also offers a wide range of paid services including mobile value-added services, games, and content sales. It generates the majority of its revenue from Net advertising services. Geographically, it derives revenue from China.

Share on Social Networks: